Close this search box.

Former BioMarin CEO Bienaimé named chair of Owkin

ARTICLE | Management Tracks

Plus: Dyne shares slip with CEO departing, and updates from Ardelyx and ProKidney

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst 

March 26, 2024 1:38 AM UTC

AI-based medical research company Owkin Inc. named Jean-Jacques Bienaimé as chair. Bienaimé was CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) from 2005 until 2023, and remains on the company’s board. He is also a board member at Incyte Corp. (NASDAQ:INCY), Immunome Inc. (NASDAQ:IMNM) and BIO.

Joshua Brumm is departing muscle disease company  Dyne Therapeutics Inc. (NASDAQ:DYN) as president and CEO to pursue a career in healthcare investing. He will be succeeded by John Cox, who was CEO of Repertoire Immune Medicines Inc. and rare disease company Bioverativ Inc. Shares of Dyne fell 8% to $26.06 on Monday…